An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
Vasomune Therapeutics, Inc., ("Vasomune"), a clinical-stage biopharmaceutical company, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results